COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.

Published in: Breast cancer research and treatment (2019)

We conclude that targeting mutant p53 with COTI-2 is a potential approach for treating p53-mutated TNBC.

Keyphrases